Tag: CELLB9®
October 29, 2019
PreveCeutical Announces Successful Completion from its Design, Synthesis and Preliminary Evaluation of Novel Designed Peptides Derived from Caribbean Blue Scorpion Venom in a Cell-Based Brain Cancer Model
PreveCeutical Medical Inc. (CSE:PREV, OTCQB:PRVCF, FSE:18H) (the “Company” or “PreveCeutical”), is pleased to announce the successful completion of the design, synthesis and...
October 7, 2019
PreveCeutical Receives $616,802 AUD Research and Development Tax Incentive Cash Refund
PreveCeutical Medical Inc. is pleased to announce that it has received a cash refund of $616,802 AUD from the Australian...
September 23, 2019
PreveCeutical Announces the Successful Engineering & Cell-Based Efficacy Screening of its Smart-siRNA Constructs for its Dual Gene Therapy Research Program
PreveCeutical Medical Inc. (CSE:PREV, OTCQB: PRVCF, FSE:18H), is pleased to provide an update on its dual gene therapy program.
September 3, 2019
PreveCeutical Reaches Milestone in Research Program for Development of Non-Addictive Analgesics
PreveCeutical Medical Inc. (CSE:PREV, OTCQB:PRVCF, FSE:18H) (the "Company" or "PreveCeutical"), is pleased to announce that it has recently reached a significant...
March 25, 2019
PreveCeutical Announces Default Judgment Against Essos Corporate Services Inc. and Detona Capital Corp.
PreveCeutical Medical Inc. (CSE:PREV, OTC:PRVCF, FSE:18H) (the "Company" or "PreveCeutical"), announces that it has obtained a default judgement against each...
March 11, 2019
PreveCeutical Announces Preliminary Screening Results of Peptides Derived From Blue Scorpion Venom in a Cell-Based Brain Cancer Model
PreveCeutical Medical Inc. (CSE:PREV) (OTC:PRVCF) (FSE:18H) (the "Company" or "PreveCeutical"), is pleased to announce positive results from the preliminary screening of key...
February 13, 2019